1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Royalty Pharma plc

Royalty Pharma plc

RPRX
Royalty Pharma plcUS flagNASDAQ Global Select
54.87
USD
-0.42
- -
23.60BMarket Cap

Total Valuation

Royalty Pharma plc carries a market capitalization of 23.60B, placing it among publicly traded companies globally. Its enterprise value stands at 31.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap23.60B
Enterprise Value31.41B

Share Statistics

Royalty Pharma plc currently has 443.63M shares outstanding.

Shares Outstanding443.63M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Royalty Pharma plc trades at a trailing price-to-earnings ratio of 25.13. The price-to-sales ratio is 8.52, and the price-to-book ratio stands at 8.29.

PE Ratio25.13
PS Ratio8.52
PB Ratio8.29
P/TBV Ratio2.31
P/FCF Ratio10.26
P/OCF Ratio7.96

Enterprise Valuation

On an enterprise value basis, Royalty Pharma plc trades at an EV/EBITDA multiple of 18.89 and an EV/FCF ratio of 10.65. The EV/Sales ratio of 12.87 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 18.94 provides insight into valuation relative to core operating earnings.

EV / Sales12.87
EV / EBITDA18.89
EV / EBIT18.94
EV / FCF10.65

Financial Position

Royalty Pharma plc maintains a current ratio of 2.66, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 90.13, indicating elevated leverage, while an interest coverage ratio of 4.95 demonstrates adequate ability to service its debt obligations.

Current Ratio2.66
Quick Ratio2.64
Debt / Equity90.13
Debt / EBITDA5.39
Interest Coverage4.95

Financial Efficiency

Royalty Pharma plc posts a return on equity of 33.17 and a return on invested capital of 9.13.

Return on Equity (ROE)33.17
Return on Assets (ROA)4.42
Return on Invested Capital (ROIC)9.13
Return on Capital Employed (ROCE)4.56
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Royalty Pharma plc's stock has gained approximately 56.32479% over the past 52 weeks. The 50-day moving average sits at 51.52, while the 200-day moving average is 42.99.

Beta (5Y)N/A
52-Week Price Change56.32479%
50-Day Moving Average51.52
200-Day Moving Average42.99
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Royalty Pharma plc generated 2.44B in revenue and converted that into 827.29M in net income, yielding earnings per share of 2.43. EBITDA reached 1.66B, while operating income came in at 1.66B.

Revenue2.44B
Gross ProfitN/A
Operating Income1.66B
Pretax Income1.36B
Net Income827.29M
EBITDA1.66B
EBIT1.66B
Earnings Per Share (EPS)2.43

Balance Sheet

Royalty Pharma plc holds 1.39B in cash and equivalents against 8.96B in total debt, resulting in a net debt position of 8.37B. Total book value stands at 2.51B, with working capital of 890.13M providing operational flexibility.

Cash & Cash Equivalents1.39B
Total Debt8.96B
Net Debt8.37B
Equity (Book Value)2.51B
Book Value Per Share5.78
Working Capital890.13M

Cash Flow

Royalty Pharma plc produced 2.61B in operating cash flow over the past twelve months.

Operating Cash Flow2.61B
Capital ExpendituresN/A
Free Cash Flow2.61B
FCF Per Share6.03

Margins

Royalty Pharma plc operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 67.93 and net profit margin of 33.90 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin67.93
Pretax Margin55.69
Profit Margin33.90
EBITDA Margin68.13

Dividends & Yields

The company's payout ratio of 20.49 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.89
Dividend YieldN/A
Payout Ratio20.49
Shareholder Yield2.49
FCF Yield9.75

Scores

Royalty Pharma plc posts an Altman Z-Score of 1.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.92